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ABSTRACT
The distribution and pharmacological properties of pituitary ad-
enylate cyclase-activating polypeptide (PACAP) receptors were stud-
ied in the fetal human adrenal gland during the second trimester of
gestation. Autoradiographic studies, using [125I]PACAP27 as a ra-
dioligand, revealed that PACAP-binding sites are exclusively located
on chromaffin cells of adrenals from fetuses 14–20 weeks old. Bio-
chemical characterization of binding revealed the occurrence of a
single class of PACAP-binding sites with a dissociation constant value
of 0.32–0.74 nmol/L and a binding capacity of 0.30–0.81 pmol/mg wet
tissue. PACAP27 and PACAP38 were equipotent in competing for
[125I]PACAP27 binding (IC50 5 0.28–0.64 nmol/L and 0.15–0.81
nmol/L, respectively), and the Hill coefficients were close to 1. In
contrast, vasoactive intestinal polypeptide was much less efficient in
displacing the tracer (IC50 5 4–362 nmol/L), and the Hill coefficients
were less than 0.6. PACAP38 induced a dose-dependent increase in
cAMP production in fetal human adrenal cell suspension (ED50 5
0.07 6 0.02 nmol/L), as well as in cells maintained in culture for 5 days
(5.4 6 1.8 nmol/L). In constrast, PACAP38 induced a modest increase
in inositol phosphate formation. These data indicate that type I
PACAP receptors are present in the early stages of the human me-
dulla organization during the process of migration of chromaffin cells
from the periphery to the central part of the gland. The present results
suggest that PACAP could be involved in the regulation of the human
adrenochromaffin cells during ontogenesis. (J Clin Endocrinol Metab
83: 1299–1305, 1998)
PITUITARY adenylate cyclase-activating polypeptide(PACAP) is a 38-amino acid a-amidated neuropeptide
initially isolated from the ovine hypothalamus because of its
ability to stimulate adenylyl cyclase activity in rat anterior
pituitary cells (1). PACAP38 possesses an internal cleavage-
amidation consensus sequence (Gly28-Lys29-Arg30) and can
thus generate a 27-residue a-amidated peptide (PACAP27)
that exhibits the same biological activity as PACAP38 (2, 3).
The NH2-terminal region of PACAP shows 68% sequence
similarity with vasoactive intestinal polypeptide (VIP), iden-
tifying PACAP as a member of the VIP/secretin/glucagon
superfamily. The primary structure of PACAP has been re-
markably conserved during evolution (4), indicating that the
peptide plays important biological functions.
Two types of PACAP-binding sites have been charac-
terized so far (see Ref. 5 for review). Type I binding sites
have a high affinity (dissociation constant (Kd) ; 0.2
nmol/L) for PACAP38 and PACAP27 and a much lower
affinity (Kd ; 1 mmol/L) for VIP (5, 6), whereas type II
binding sites have similar affinity for PACAP38,
PACAP27, and VIP (7). Both receptor subtypes belong to
the seven-transmembrane domain G protein-coupled re-
ceptor superfamily (8 –10) and are differentially coupled to
adenylyl cyclase and phospholipase C (10). PACAP and
PACAP-binding sites are widely distributed in the central
nervous system and in peripheral organs (7, 11). In par-
ticular, the occurrence of PACAP and its recognition sites
has been demonstrated in various endocrine glands, in-
cluding the pituitary, pancreas, testis, ovary, and adrenal
(3, 5, 7, 12, 13).
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Developmental studies have shown that, in the brain, the
expression of PACAP and PACAP-binding sites undergoes
important variations during ontogenesis. For instance, a high
concentration of PACAP has been detected in the rat cere-
bellum between postnatal days 4 and 20 (14, 15). Similarly,
intense expression of PACAP receptors has been observed in
the proliferative zone of the cerebellar cortex during the
postnatal period (16, 17), suggesting that PACAP exerts neu-
rotrophic activities during development. In support of this
hypothesis, it has been shown that PACAP promotes cell
survival and neurite outgrowth in cultured cerebellar gran-
ule cells (18) and stimulates proliferation of folliculo-stellate
cells (19).
The occurrence of PACAP and PACAP receptors in the
adult adrenal gland (13, 20–22) and the observation that
PACAP modulates proliferation and differentiation of ad-
renal chromaffin cells (23–25) suggest that PACAP may play
a role in the ontogeny of the adrenal gland. The fetal human
adrenal gland is composed of morphologically and func-
tionally distinct steroid-secreting tissues: a thin neocortex
that produces cortisol and a large fetal zone that produces
massive amounts of dehydroepiandrosterone sulfate (26, 27).
During fetal life, cells derived from the ectoderm migrate
inside the gland to form the medulla (28, 29). After birth, the
fetal zone involutes, and the cortex develops and differen-
tiates into the three characteristic zones present in the adult
adrenal gland. These profound changes in the organization
of the gland suggest that trophic factors, such as PACAP,
may control the modeling of the tissue during ontogenesis.
However, the distribution and function of PACAP receptors
have not yet been studied in the adrenal during
development.
In the present study, we have localized PACAP-binding
sites in the fetal human adrenal gland by autoradiography,
and we have investigated the effect of PACAP on second-
messenger systems in suspended and cultured fetal adrenal
cells.
Materials and Methods
Reagents and peptides
Myo-[3H]inositol (10–20 Ci/mmol) and [3H]adenine (24 Ci/mmol)
were purchased from Amersham (Oakville, Ontario, Canada). Na125I
(2000 Ci/mmol) was obtained from Amersham (Les Ulis, France). ATP,
cAMP, and deoxyribonuclease were supplied by Sigma (St. Louis, MO).
Eagle’s MEM, collagenase, and Opti-MEM medium were obtained from
Gibco (Burlington, Ontario, Canada). PACAP27 was from Bachem (Ma-
rina Delphen, CA). BSA was from Boehringer (Mannheim, Germany).
PACAP38 and VIP were synthesized by the solid-phase methodology
previously described (30).
Monoiodinated PACAP27 was used as a tracer. Iodination of syn-
thetic PACAP27 was performed by means of the lactoperoxidase tech-
nique, and the radioligand was purified by reverse-phase high-perfor-
mance liquid chromatography, as previously described (31, 32). The
specific radioactivity of the radioligand was approximately 800
Ci/mmol.
Tissue preparation
Fetal human adrenal glands were obtained from fetuses between
14 and 20 weeks old (post conception) at the time of therapeutic
abortion. Fetal ages were estimated by foot length and time after the
last menstruation, according to Streeter (33). After removal, glands
were kept on ice in McCoy’s medium and transported within 4 h to
the laboratory. The project was approved by the human subject re-
view committees at our institutions. Immediately after collection,
glands were cleansed of fat and were either frozen at 280 C or
processed for cell dispersion.
Autoradiographic studies
Frozen adrenal glands were sliced into 10-mm sections on a cryostat
(Frigocut, Reicher-Jung, Germany). Sections were thaw-mounted on
gelatin-coated slides, placed in a desiccator overnight at 4 C, and pro-
cessed for autoradiography, as previously described (16). Tissue slices
were preincubated for 30 min at 24 C in 50 mmol/L Tris buffer (pH 7.4)
containing 1% BSA, 5 mmol/L MgCl2, 32 mmol/L sucrose, and 0.5
mg/mL bacitracin. The sections were incubated with [125I]PACAP27 (50
pmol/L) for 2 h at 24 C in the same buffer, supplemented with 2% BSA
and 100 KIU/mL aprotinin (Hoechst Laboratories, Puteaux, France).
Nonspecific binding was determined by adding 1 mmol/L PACAP27.
For competition studies, the sections were incubated with 50 pmol/L
tracer in the presence of various concentrations of unlabeled PACAP27,
PACAP38 (10210 to 1026 mol/L) or VIP (1029 to 1026 mol/L). The slices
were washed three times for 5-min periods at 4 C in 50 mmol/L Tris
buffer containing 0.1% BSA, 5 mmol/L MgCl2, and 0.5 mg/mL bacitra-
cin. Finally, the sections were dried under a cold-air stream and apposed
onto Amersham Hyperfilm-3H for 10 days.
The gray levels of the autoradiograms were measured by means of
a computer-assisted image analysis station BIO 500 (Biocom, Les Ulis,
France), as previously described (34). The concentration of ligand which
causes 50% inhibition of the binding values (IC50) and Hill coefficients
were determined using the Sigma Plot program (Jandel Scientific, Corte
Madera, CA).
Histochemical and immunological procedures
After exposure for autoradiography, adrenal sections were fixed with
vapors of paraformaldehyde (24 h, 60 C). Tissue slices were either
stained with hematoxylin-eosin or immunostained with antibodies
against human chromogranin A (CgA; Dako, Glostrup, Denmark), a
marker of chromaffin cells (29). Briefly, tissue sections were incubated
overnight at 4 C with the CgA antiserum, diluted 1:100 in phosphate
buffer (PB; 0.1 mol/L, pH 7.4) containing 0.3% Triton X-100 and 1% BSA.
After several rinses in PB, the sections were incubated for 90 min at room
temperature with fluorescein isothyocyanate-conjugated goat antirabbit
g-globulins (GAR/FITC; Caltag Laboratories, San Francisco, CA) di-
luted 1:100. Finally, the sections were rinsed in PB and mounted in
PB/glycerol (1:1). The preparations were examined on a Leitz Orthoplan
(Heidelberg, Germany) microscope equipped with a photographic
system.
Dissociation of adrenal cells
The adrenal glands from 18- to 20-week-old fetuses were finely
chopped into 1- to 2-mm pieces. The tissue fragments were subjected to
enzymatic dissociation in Eagle’s MEM containing collagenase (2 mg/
mL) and deoxyribonuclease (25 mg/mL), as previously described (35).
The tissue was mechanically dissociated by gentle aspiration, and dis-
persed cells were filtered and centrifuged for 10 min at 100 3 g. The cell
pellet was resuspended in Opti-MEM containing 2% FBS, 100 U/mL
penicillin, and 100 mg/mL streptomycin. Cells were plated in 35-mm
Petri dishes at a density of about 2.5 3 105 cells per dish and were grown
in a humidified atmosphere of 95% air-5% CO2 at 37 C. The culture
medium was changed 24 h after seeding, and cells were used after 5 days
of culture. For studies using suspended cells, cells were incubated in
culture medium for a resting period of 12 h. After centrifugation (10 min;
100 3 g), cells were suspended in Hank’s buffered saline (HBS)-glucose
(HBS: NaCl, 130 mmol/L; KCl, 3.5 mmol/L; CaCl2, 1.8 mmol/L; MgCl2,
0.5 mmol/L; NaHCO3, 2.5 mmol/L; HEPES, 5 mmol/L) at a density of
5 3 105 cells/tube.
Cyclic AMP determination
Cyclic AMP production was determined by measuring the conver-
sion of [3H]ATP into [3H]cAMP, as previously described (36). Briefly,
cultured cells were incubated at 37 C for 1 h in Opti-MEM culture
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medium containing 2 mCi/mL [3H]adenine. The cultures were washed
with HBS buffer and incubated in the same buffer, containing 1 mmol/L
isobutyl methylxanthine, for 15 min at 37 C. Cultured cells were incu-
bated with PACAP38 for an additional 15 min at 37 C. The reaction was
stopped by aspiration of the medium and addition of 1 mL 5% trichlo-
roacetic acid. Cells were scraped with a rubber policeman, and 100 mL
of cold solution of ATP and cAMP (5 mmol/L each) was added to the
mixture. Cell membranes were pelleted at 5,000 3 g for 15 min, and the
supernatants were sequentially chromatographed on Dowex and alu-
mina columns, as previously described (37), allowing the separation of
[3H]ATP nucleotide from [3H]cAMP. cAMP formation was expressed as:
% conversion 5 ([3H]cAMP/([3H]cAMP 1 [3H]ATP) 3 100 per 15 min.
Measurement of inositol phosphate (InsP) formation
The effect of PACAP on polyphosphoinositide metabolism was
investigated as described previously (38). Briefly, cells were grown
for 2 days in Opti-MEM culture medium containing 2 mCi/mL myo-
[3H]inositol. The radioactive medium was then discarded, and the
cells were incubated in isotope-free and serum-free culture medium.
After 30 min, cells were washed, incubated for 15 min in HBS-glu-
cose/LiCl (10 mmol/L) medium, and incubated for another 15 min
at 37 C with PACAP38 in the same medium. The incubation was
stopped by aspiration of the medium and addition of 1 mL of 5%
(vol/vol) perchloric acid and 200 mL BSA (20 mg/mL). Total InsPs
were separated by ion exchange chromatography on (1 3 8 cm)
Dowex columns. The radioactivity found in the InsP fractions was
determined by scintillation counting in gel phase in a Beckman b
counter.
Data analysis
The data are presented as means 6 se. Statistical analysis was per-
formed using the one-way ANOVA test. Homogeneity of variance was
assessed by Bartlett’s test, and P values were obtained from Dunnett’s
tables.
Results
Localization of PACAP-binding sites
The autoradiographic localization of [125I]PACAP27-bind-
ing sites was performed in the adrenal of fetuses at 14–20
weeks of gestation. The distribution of the binding sites in a
16-week-old fetus is illustrated in Fig. 1A. Labeling of con-
secutive sections with antibodies against human CgA dem-
onstrated that the autoradiographic labeling was restricted to
the chromaffin tissue (Fig. 1, A and B). Histochemical stain-
ing of tissue sections with hematoxylin-eosin showed that
chromaffin cells formed radial clusters, penetrating the eosi-
nophilic cells of the fetal zone (Fig. 1C). At all developmental
stages studied, PACAP-binding sites were found only in the
fetal medullary zone.
Characterization of PACAP-binding sites
Figure 2 illustrates the displacement of [125I]PACAP27
binding (Fig. 2A) by increasing concentrations of synthetic
PACAP27 (Fig. 2, B–D), PACAP38 (Fig. 2, E–G), or VIP (Fig.
2, H–J) on consecutive sections of a fetal adrenal gland at 15
weeks of gestation. Incubation of tissue slices with 1028
mol/L PACAP27 (Fig. 2C) or PACAP38 (Fig. 2F) completely
abolished the autoradiographic labeling. In contrast, at the
same dose, VIP induced only a slight displacement of
[125I]PACAP27 binding (Fig. 2I).
Similar experiments were performed on adrenal slices
from 14- to 20-week-old fetuses, and the autoradiographic
labeling was quantified using a computer-assisted image
analyzer. At all stages studied, PACAP27 and PACAP38
were more potent than VIP in displacing [125I]PACAP27
binding (Fig. 3, A–F). Scatchard plot analysis of PACAP27
inhibition curves (Fig. 3B inset) revealed that the affinity
of PACAP-binding sites and the density of sites were
relatively constant throughout the gestation period stud-
ied (Table 1). PACAP27 and PACAP38 were equally potent
in displacing [125I]PACAP27, whereas VIP was 20 to 500
times less potent than PACAP27 in competing with the
tracer during the whole period studied (Table 2). The
values of the Hill coefficient were close to 1 for PACAP27
and slightly lower for PACAP38, but systematically infe-
rior to 0.6 for VIP (Table 2).
Effect of PACAP on second-messenger coupling
The capacity of PACAP38 to stimulate cAMP produc-
tion was measured both in cell suspensions (used after a
12-h resting period) and in cells cultured for 5 days. In
suspended cells, PACAP38 induced a dose-dependent in-
crease in the conversion of ATP into cAMP (Fig. 4A). The
ED50 value was 0.07 6 0.02 nmol/L, and the maximum
FIG. 1. Microphotographs of sections of an adrenal gland from a 16-
week-old human fetus. A, Autoradiographic localization of
[125I]PACAP27-binding sites; B, immunohistofluorescent localization
of chromogranin A-containing cells; C, hematoxylin-eosin staining;
CC, chromaffin cells; FZ, fetal zone; NC, neocortex. Bars: 1.4 mm (A);
0.6 mm (B); 0.2 mm (C).
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effect was reached at a dose of 10 nmol/L, with a stimu-
lation ratio of 2.55 6 0.25 (n 5 7, P , 0.01) over basal value.
In cultured cells, the basal conversion of ATP into cAMP
was significantly lower than in suspended cells. The ED50
value was 5.4 6 1.8 nmol/L, and the maximal effect was
reached at a dose of 100 nmol/L, with a stimulation ratio
of 3.4 6 0.40 (n 5 9, P , 0.001) over basal value. In contrast,
PACAP38 did not affect InsP accumulation in suspended
adrenal cells from 20-week-old fetuses but only induced a
modest increase of InsP content (1.30-fold over control) in
cells from 15- to 16-week-old fetuses (data not shown).
Discussion
The presence of PACAP in the adrenal gland and the effect
of the neuropeptide on catecholamine and steroid secretion
have been documented in various mammalian species. In
contrast, little is known concerning the possible role of
PACAP in the human adrenal gland. The present study pro-
vides the first evidence for the occurrence of functional
PACAP receptors in fetal chromaffin cells.
Localization and characterization of PACAP-binding sites
Autoradiographic labeling, using [125I]PACAP27 as a
radioligand, revealed the presence of a high density of
binding sites in the central zone of the gland. Immuno-
histochemical staining of adrenal slices with antibodies
against human CgA, a selective marker of neuroendocrine
cells (29), demonstrated that PACAP-binding sites are ex-
clusively borne by chromaffin cells. The strong autora-
diographic signal observed at the earlier stage studied
(14-week-old fetuses) is consistent with previous reports
indicating that, in the developing human adrenal gland,
chromaffin cells establish their phenotype as early as 6
weeks of gestation, as evidenced by the expression of CgA
and tyrosine hydroxylase (29, 39). The fetal human adrenal
cortex is composed of a thin outer zone (neocortex) and a
large fetal zone that represents over 80% of the gland (26,
27). The present study showed that both of these cortical
zones are virtually devoid of PACAP-binding sites. In
agreement with this observation, autoradiographic label-
ing, membrane binding assay, and in situ hybridization
immunohistochemistry studies indicate that, in the adult
rat adrenal gland, PACAP-binding sites are located only
on chromaffin cells (20 –22).
Scatchard plot analysis of PACAP-binding in the fetal
human chromaffin tissue showed the existence of high-
affinity binding sites with Kd values ranging from 0.32–
0.74 nmol/L. Displacement experiments demonstrated
that PACAP27 and PACAP38 were equally potent in com-
peting with the radioligand at all developmental stages
studied, whereas VIP was a much weaker competitor.
These data revealed that the binding sites evidenced with
[125I]PACAP27 correspond predominantly to type I
PACAP receptors. The fact that the Hill coefficients mea-
sured with PACAP27 were close to 1 suggested that the
peptide interacts with a single class of receptors. However,
the lower Hill coefficient value calculated with VIP as a
competitor would indicate the existence of a heteroge-
neous population of PACAP/VIP receptors, as previously
reported in rat (20, 40, 41) and human adult adrenal me-
dulla (42).
Second-messenger coupling of PACAP receptors
There is now clear evidence that type I PACAP receptors
can be coupled to adenylyl cyclase and phospholipase C
(6–7, 10). We have thus investigated the transduction mech-
anisms associated with the PACAP binding sites in fetal
human adrenomedullary cells. We found that PACAP38
stimulated, in a dose-dependent manner, cAMP production
from both isolated and cultured adrenal cells. The concen-
FIG. 2. Typical autoradiograms show-
ing the displacement of [125I]PACAP27
binding (A) by graded doses of unla-
beled PACAP27 (B–D), PACAP38 (E–
G), or VIP (H–J). All autoradiograms
were obtained from 10-mm consecutive
sections of an adrenal gland from a 15-
week-old human fetus. Bar: 2 mm
(A–J).
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tration of ligand which causes 50% inhibition of the binding
(IC50) for PACAP27 binding and the ED50 for cAMP forma-
tion were in the same range (0.3 and 0.07 nmol/L, respec-
tively), showing the existence of a good correlation between
binding and coupling potency. These data indicate that the
binding sites visualized by autoradiography actually cor-
respond to functional receptors positively coupled to ad-
enylyl cyclase. However, although PACAP38 stimulates
both adenylyl cyclase and phospholipase C activity in
porcine adrenochromaffin cells (43), we found that
PACAP causes only a slight increase in InsP formation.
The modest effect of PACAP on phospholipase C activity
suggests that fetal human adrenal cells express either the
SV1 or the SV3 splice variants of the PACAP receptor,
which exhibit a low efficacy for phospholipase C activa-
tion (44). Alternatively, the Gq protein, which is required
for receptor coupling to phospholipase C, may be ex-
pressed at a very low level at this stage of fetal develop-
ment in human adrenochromaffin cells. In support of this
latter hypothesis, we found that fluoroaluminate, a non-
specific activator of all heterotrimeric G proteins, induces
a 2-fold increase in InsP production in fetal adrenal cells,
compared with a 15-fold increase in adult cells (data not
shown).
Functional implications
The role of PACAP in the human adrenal during devel-
opment is currently unknown. In vivo and in vitro studies on
animal models have shown that PACAP stimulates tyrosine
hydroxylase activity and catecholamine secretion from chro-
maffin cells (21, 43, 45). It has recently been reported that
PACAP also enhances catecholamine release from adult hu-
man adrenal explants (46). These data suggest that PACAP
may also exert a stimulatory effect on catecholamine secre-
tion by fetal adrenochromaffin cells. In support of this hy-
pothesis, immunohistochemical studies have shown the
presence of both tyrosine hydroxylase and dopamine
b-hydroxylase in human chromaffin cells at early stages of
development (28, 39).
In the adult human adrenal gland, Neri et al. (46) have
shown that PACAP stimulates aldosterone and 18-OH-cor-
ticosterone secretion, probably via an indirect mechanism
involving the release of catecholamines by chromaffin cells.
This paracrine effect of PACAP in the adult adrenal tissue is
facilitated by the existence of islets and medullary rays
within the adrenal cortex (47, 48). In the fetal human adrenal,
a paracrine mode of action is even more plausible, inasmuch
as, during ontogenesis, chromaffin cells migrate centripetally
through the cortex towards their central destination (29, 39).
PACAP is known to act as a growth factor, modulating
proliferation, survival, and differentiation of various types of
neuronal cells (18, 49, 50). In particular, PACAP has been
shown to induce neurite outgrowth and tyrosine hydroxy-
lase gene expression in cultured rat chromaffin cells (24, 25)
and PC12 cells (51). It is thus conceivable that PACAP also
may affect the migration and/or differentiation of immature
human chromaffin cells.
In conclusion, the present study has shown that type I
PACAP receptors are expressed in human chromaffin cells in
14- to 20-week-old fetuses and that these receptors are func-
tionally coupled to adenylyl cyclase. These data suggest that
PACAP may play a role in the differentiation and/or secre-
TABLE 1. Affinity and binding capacity of [125I]PACAP27 binding
sites in the fetal human adrenal
Weeks of
gestation Kd (nmol/L)
Bmax
(pmol/mg wet tissue)
14 0.39 6 0.10 0.43 6 0.14
15 0.37 6 0.07 0.30 6 0.06
16 0.54 6 0.01 0.35 6 0.02
17 0.74 6 0.04 0.46 6 0.05
18 0.54 6 0.06 0.81 6 0.10
19 0.32 6 0.03 0.35 6 0.07
20 0.59 6 0.04 0.69 6 0.09
Sections of fetal adrenal glands were processed for autoradiogra-
phy as described in Materials and Methods. Kd and Bmax values were
determined from Scatchard plot analysis of competition studies using
PACAP27 as a competitor. Results are the mean 6 SE. Bmax, binding
capacity.
FIG. 3. Representative competition curves showing the displacement
of [125I]PACAP27 binding on adrenal slices from human fetuses by
graded concentrations of unlabeled PACAP27 (E-E), PACAP38 (F-F),
or VIP (-). The curves were obtained by quantification of autora-
diograms similar to those shown in Fig. 2. The six graphs correspond
to six different ages of gestation: A, 14 weeks; B, 15 weeks; C, 16
weeks; D, 18 weeks; E, 19 weeks; and F, 20 weeks. Inset, Scatchard
representation of the displacement curve by PACAP27, shown in B.
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tory activity of chromaffin cells in the fetal human adrenal
gland.
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